Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A T Reder

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Neurology|March 29, 2007
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin, E M Frohman, B Hurwitz, et al.
Neurology|December 1, 1996
Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1bN H Pliskin, D P Hamer, D S Goldstein, et al.
Neurology|March 1, 2006
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosisB Banwell, A T Reder, L Krupp, et al.
Science (New York, N.Y.)|October 31, 1986
Neuroleukin: a lymphokine product of lectin-stimulated T cellsM E Gurney, B R Apatoff, G T Spear, et al.
Neurology|June 10, 2010
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MSA T Reder, G C Ebers, A Traboulsee, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 22, 2010
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trialG C Ebers, A Traboulsee, D Li, et al.
Neurology|July 9, 2008
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisR Zivadinov, A T Reder, M Filippi, et al.
Annals of Neurology|October 1, 1995
Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosisJ N Whitaker, R D Kachelhofer, E L Bradley, et al.
Neurology|June 1, 1995
Clinical and genetic studies of fatal familial insomniaA T Reder, A S Mednick, P Brown, et al.
Neurology|April 13, 2012
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trialD S Goodin, A T Reder, G C Ebers, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Neurology|March 29, 2007
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of NeurologyD S Goodin, E M Frohman, B Hurwitz, et al.
Neurology|December 1, 1996
Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1bN H Pliskin, D P Hamer, D S Goldstein, et al.
Neurology|March 1, 2006
Safety and tolerability of interferon beta-1b in pediatric multiple sclerosisB Banwell, A T Reder, L Krupp, et al.
Science (New York, N.Y.)|October 31, 1986
Neuroleukin: a lymphokine product of lectin-stimulated T cellsM E Gurney, B R Apatoff, G T Spear, et al.
Neurology|June 10, 2010
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MSA T Reder, G C Ebers, A Traboulsee, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 22, 2010
Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trialG C Ebers, A Traboulsee, D Li, et al.
Neurology|July 9, 2008
Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisR Zivadinov, A T Reder, M Filippi, et al.
Annals of Neurology|October 1, 1995
Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosisJ N Whitaker, R D Kachelhofer, E L Bradley, et al.
Neurology|June 1, 1995
Clinical and genetic studies of fatal familial insomniaA T Reder, A S Mednick, P Brown, et al.
Neurology|April 13, 2012
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trialD S Goodin, A T Reder, G C Ebers, et al.
Pageof 8